Stereotactic body radiation therapy for primary kidney cancer

The incidence of primary renal cancer is increasing, particularly in elderly patients who may have comorbidities and/or a surgical contraindications. Stereotactic body radiotherapy has primarily been evaluated retrospectively to date. The most commonly used dose schedules are 40 Gy in five fractions, 42 Gy in three fractions, and 26 Gy in one fraction. The results in terms of local control and toxicity are very encouraging. The advantages of stereotactic body radiotherapy compared to thermal ablative treatments are its non-invasive nature, absence of general anesthesia, ability to treat larger lesions, and those close to the renal hilum. Prospective evaluations are still necessary. (c) 2023 Societe franc, aise de radiotherapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.